SMT201700019B - Combinazione di composizioni di antagonisti di adenosina a1 e bloccanti di recettori non selettivi beta-adrenergici per ridurre la pressione intraoculare - Google Patents

Combinazione di composizioni di antagonisti di adenosina a1 e bloccanti di recettori non selettivi beta-adrenergici per ridurre la pressione intraoculare

Info

Publication number
SMT201700019B
SMT201700019B SM201700019T SM201700019T SMT201700019B SM T201700019 B SMT201700019 B SM T201700019B SM 201700019 T SM201700019 T SM 201700019T SM 201700019 T SM201700019 T SM 201700019T SM T201700019 B SMT201700019 B SM T201700019B
Authority
SM
San Marino
Prior art keywords
adenosine
combination
intraocular pressure
adrenergic receptor
receptor blockers
Prior art date
Application number
SM201700019T
Other languages
English (en)
Inventor
Norman N Kim
William K Mcvicar
Thomas G Mccauley
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of SMT201700019B publication Critical patent/SMT201700019B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM201700019T 2010-03-19 2017-01-16 Combinazione di composizioni di antagonisti di adenosina a1 e bloccanti di recettori non selettivi beta-adrenergici per ridurre la pressione intraoculare SMT201700019B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31572110P 2010-03-19 2010-03-19
PCT/US2011/029010 WO2011116290A1 (en) 2010-03-19 2011-03-18 Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure

Publications (1)

Publication Number Publication Date
SMT201700019B true SMT201700019B (it) 2017-03-08

Family

ID=44649619

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20170019T SMT201700019T1 (it) 2010-03-19 2011-03-18 Combinazione di composizioni di antagonisti di adenosina a1 e bloccanti di recettori non selettivi beta-adrenergici per ridurre la pressione intraoculare
SM201700019T SMT201700019B (it) 2010-03-19 2017-01-16 Combinazione di composizioni di antagonisti di adenosina a1 e bloccanti di recettori non selettivi beta-adrenergici per ridurre la pressione intraoculare

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM20170019T SMT201700019T1 (it) 2010-03-19 2011-03-18 Combinazione di composizioni di antagonisti di adenosina a1 e bloccanti di recettori non selettivi beta-adrenergici per ridurre la pressione intraoculare

Country Status (17)

Country Link
US (1) US8440639B2 (it)
EP (1) EP2555775B1 (it)
JP (1) JP2013522322A (it)
CN (1) CN102933220A (it)
CY (1) CY1118495T1 (it)
DK (1) DK2555775T3 (it)
ES (1) ES2613254T3 (it)
HR (1) HRP20170008T1 (it)
HU (1) HUE031529T2 (it)
LT (1) LT2555775T (it)
ME (1) ME02593B (it)
PL (1) PL2555775T3 (it)
PT (1) PT2555775T (it)
RS (1) RS55617B1 (it)
SI (1) SI2555775T1 (it)
SM (2) SMT201700019T1 (it)
WO (1) WO2011116290A1 (it)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2424546E (pt) * 2009-05-01 2015-12-23 Inotek Pharmaceuticals Corp Método de redução de pressão intraocular em seres humanos
LT2523669T (lt) 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Akispūdžio mažinimo būdas, derinys ir rinkinys
AU2011230580A1 (en) * 2010-03-26 2012-10-11 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
PL2807178T3 (pl) * 2012-01-26 2017-12-29 Inotek Pharmaceuticals Corporation Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania
WO2014152723A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
CN107406479A (zh) * 2014-12-03 2017-11-28 伊诺泰克制药公司 预防、减轻或治疗黄斑变性的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423144B2 (en) 2004-05-26 2008-09-09 Inotek Pharmaceuticals Corporation Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
CN101010085B (zh) 2004-05-26 2012-12-26 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
BRPI0619261A2 (pt) * 2005-11-30 2011-09-27 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso desses
PT2424546E (pt) * 2009-05-01 2015-12-23 Inotek Pharmaceuticals Corp Método de redução de pressão intraocular em seres humanos

Also Published As

Publication number Publication date
ME02593B (me) 2017-06-20
EP2555775B1 (en) 2016-12-07
HRP20170008T1 (hr) 2017-03-10
US20110245193A1 (en) 2011-10-06
PT2555775T (pt) 2017-02-01
ES2613254T3 (es) 2017-05-23
WO2011116290A1 (en) 2011-09-22
CN102933220A (zh) 2013-02-13
EP2555775A1 (en) 2013-02-13
HUE031529T2 (en) 2017-07-28
SI2555775T1 (sl) 2017-05-31
JP2013522322A (ja) 2013-06-13
DK2555775T3 (en) 2017-02-06
PL2555775T3 (pl) 2017-08-31
SMT201700019T1 (it) 2017-03-08
EP2555775A4 (en) 2013-08-28
LT2555775T (lt) 2017-04-25
US8440639B2 (en) 2013-05-14
RS55617B1 (sr) 2017-06-30
CY1118495T1 (el) 2017-07-12

Similar Documents

Publication Publication Date Title
SMT201700020B (it) Combinazione di composizioni di antagonisti di adenosina a1 e bloccanti di recettori non selettivi beta-adrenergici per ridurre la pressione intraoculare
BR112012003263A2 (pt) formulações intravenosas de antagonistas de neuroquinina-1
PT2638042E (pt) Antagonista do recetor do cgrp de piperidinona carboxamida azaindano
BR112012005237A2 (pt) utilização de composições ternárias
SMT201600078B (it) Antagonista del recettore per cgrp
EP2427430A4 (en) 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS
EP2585064A4 (en) C5aR Antagonist
EP2619204A4 (en) TRIAZOLOPYRAZINONE AS P2X7 RECEPTOR ANTAGONISTS
EP2638046A4 (en) SPIRO-oxindole-MDM2 ANTAGONISTS
EP2400987A4 (en) Benda MUSTIN-CYCLOPOLYSACCHARIDZUSAMMENSETZUNGEN
SMT201600150B (it) Antagonisti di trpv4
EP2480576A4 (en) PCSK9 ANTAGONISTS
ME02965B (me) Kombinacije antagonista muskarinskog receptora i agonista вета - 2 adrenoreceptora
EP2771001A4 (en) PIPERIDINYL-alkyne-orexin
EP2693175A4 (en) MORE HEAD SCALE
BR112012000907A2 (pt) copolimero de impacto para preparar um copolimero de impacto
EP2461809A4 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
SMT201400023B (it) Analoghi di buprenorfina
BRPI1007981A2 (pt) composições de cunha líquidas de duas partes
EP2485737A4 (en) NEW TRPA1 ANTAGONISTS
EP2394844A4 (en) SEAT SUSPENSION
DK2607363T3 (da) Kondenseret ringforbindelse til anvendelse som mineralokortikoid-receptorantagonist
BR112012003976A2 (pt) antagonistas de receptor glyt1 carbocíclico
BRPI1008925A2 (pt) estrutura de montagem de partes de componentes
BRPI1008008A2 (pt) usos de antagonistas do receptor de nk